Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases

Seminars in Interventional Radiology

Volumn 23, Issue 1, 2006, Pages 99-108

  Brown, Kevin S ^a,b  

^a Mail Code 4000 ^*  (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Liver metastases; Systemic Therapy

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CLADRIBINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GONADORELIN; IRINOTECAN; MEGESTROL ACETATE; MITOMYCIN C; MITOXANTRONE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DNA DRUG COMPLEX; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG INHIBITION; DRUG METABOLISM; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTESTINE PERFORATION; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; LIVER METASTASIS; LOCAL THERAPY; LUNG CANCER; META ANALYSIS; MULTIPLE MYELOMA; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS CANCER; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN THROMBOSIS;

EID: 33646082983     PISSN: 07399529     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939845     Document Type: Review

References (81)

1. Park JG, Lee SK, Hong IG, et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994;86:700-705
2. Park NH, Chung YH, Youn KH, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol 2001;33:397-401
3. Valle JW, Dangoor A, Beech J, et al. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin: results of a phase II study. Br J Cancer 2005;92:628-630
4. Hochster HS, Greeni MD, Speyer J, et al. 4′-Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985;3:1535-1540
5. Pohl J, Zuna I, Stremmel W, et al. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001;47:359-365
6. Dunk AA, Scott SC, Johnson PJ, et al. Mitozantrone as single agent therapy in hepatocellular carcinoma: a phase II study. J Hepatol 1985;1:395-404
7. Colleoni M, Nole F, Di Bartolomeo M, et al. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology 1992;49:139-142
8. Tetef M, Doroshow J, Akman S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995;13:460-463
9. Link JS, Bateman JR, Paroly WS, et al. 5-Fluorouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer 1977;39:1936-1939
10. Porta C, Moroni M, Nastasi G, et al. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995;52:487-491
11. Lozano RD, Patt YZ, Hassan MM, et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer) (abstract 1025). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 20-23, 2000; New Orleans, LA
12. Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993;50:22-26
13. Shin D, Lee S, Park J, et al. Systemic chemotherapy with capecitabine, doxorubicin and cisplatin for metastatic hepatocellular carcinoma (abstract 4177). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL
14. Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004;54:385-390
15. Yang TS, Chang WC, Lin YC, et al. A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma (abstract 1351). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, IL
16. Ikeda M, Okusaka T, Ueno H, et al. A phase II trial of continuous-infusion 5-fluorouracil, mitoxantrone and cisplatin for metastatic hepatocellular carcinoma (abstract 4081). Paper presented at Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, LA
17. Kim GP, Alberts SR, Tschetter LK, et al. Gemcitabine andaocetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma, a North Central Cancer Treatment Group (NCCTG) phase II trial (abstract 4270). Paper presented at Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004; New Orleans, LA
18. Kemeny N, Kemeny M, Lawrence TS. Liver metastases. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG, eds. Clinical Oncology. Philadelphia: Elsevier Churchill Livingstone; 2004:1141-1178
19. Jang BK, Kwon KM, Chung WJ, et al. Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin. Korean J Hepatol 2004;10:271-278
20. Lin CP, Yu HC, Cheng JS, et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-fluorouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004;67:602-610
21. Ru J, Byone S, Nelson T, et al. Hepatic intra-arterial infusion (HIA) of cisplatin and mitomycin-C for hepatocellular carcinoma: the USC experience (abstract 1519). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, IL
22. Jonas S, Bechstein WO, Heinze T, et al. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Surgery 1997;121:456-461
23. Villa E, Colantoni A, Grottola A, et al. Variant estrogen receptors and their role in liver disease. Mol Cell Endocrinol 2002;193:65-69
24. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36:1221-226
25. Perrone F, Gallo C, Daniele B, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multi-centre randomized controlled trial. Curr Pharm Des 2002;8:1013-1019
26. Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-885
27. Negro F, Papotti M, Pacchioni D, et al. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridization. Liver 1994;14:213-219
28. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417
29. Manesis EK, Giannoulis G, Zoumboulis P, et al. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995;21:1535-1542
30. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766-774
31. Kouroumalis E, Skordilis P, Thermonths K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-447
32. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691
33. Radaeva S, Jaruga B, Hong F, et al. Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 2002;122:1020-1034
34. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58
35. Ji SK, Park NH, Choi HM, et al. Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Intern Med 1996;11:56-68
36. Yeo W, Zee B, Leung WT, et al. A phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma (abstract 4026). Paper presented at Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, LA
37. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-508
38. Rajkumar SV, Fonseca R, Witzig TE, et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999;13:469-472
39. Argiles JM, Carbo N, Lopez-Soriano FJ, et al. Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses 1998;50:313-318
40. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005;103:749-755
41. Zhu AX, Fuchs CS, Clark JW, et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 2005;10:392-398
42. Lersch C, Schmelz R, Erdmann J, et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine: a critical evaluation. Hepatogastroenterology 2004;51:1099-1103
43. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419
44. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-447
45. Gruenberger T, Schuell B, Kornek G, et al. Elderly patients do benefit from oxaliplatin based neoadjuvant chemotherapy in resectable colorectal cancer liver metastases (abstract 3601). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL
46. Bathe OF, Ernst S, Sutherland F, et al. A phase II study of neoadjuvant irinotecan, 5-fluorouracil and leucovorin for resectable liver metastases from colorectal cancer (abstract 3662). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL
47. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-964
48. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308
49. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-1047
50. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
51. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 2002;38:S15-S20
52. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaiiplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091
53. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan versus capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer (abstract 1022). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, IL
54. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345
55. Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol 2004;5:647
56. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
57. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOL-FOX-4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200 (abstract 2). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL
58. Lenz H-J, Hochster H, Wadler S, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer (abstract 3508). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL
59. Breedis C, Young C. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-985
60. Hohn D, Stagg R, Friedman M, et al. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol 1989;7:1646-1654
61. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluoroxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693
62. Martin JKJ, O'Connell MG, Wieland HS, et al. Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 1990;125:1022-1027
63. Kemeny N, Kemeny M, Lawrence T. Liver metastases. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W, eds. Clinical Oncology. Philadelphia: Elsevier Churchill Livingstone; 2004:1141-1178
64. Muss HB, Case LD, Atkins JN, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 1994;12:1630-1638
65. Manni A, Trujillo JE, Marshall JS, et al. Antihormone treatment of stage IV breast cancer. Cancer 1979;43:444-450
66. Nabholtz JM, Buzdar A, Poltak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-3757
67. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18:3748-3757
68. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606
69. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001;19:314-321
70. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-592
71. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726
72. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
73. Fraschini G, Fleishman G, Yap H-Y, et al. Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep 1987;71:313-315
74. Arai Y, Sone Y, Inaba Y, et al. Hepatic arterial infusion chemotherapy forlrver metastases from breast cancer. Cancer Chemother Pharmacol 1994;33(suppl):142-144
75. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002;346:85-91
76. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001;6(suppl 1):4-7
77. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-3137
78. Sandier AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group trial-E4599 (abstract LBA4). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL
79. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-cohlrolled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of first or second line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group trial (abstract 7022). Paper presented at Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004;New Orleans, LA
80. Bums HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413
81. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (abstract 1). Paper presented at Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL